Continuous subcutaneous infusion of AC2993 (synthetic exendin-4) provides sustained day-long glycemic control in patients with Type 2 diabetes

被引：0
|
作者：
Taylor, K [1 ]
Kim, D [1 ]
Bicsak, T [1 ]
Heintz, S [1 ]
Varns, A [1 ]
Aisporna, M [1 ]
Fineman, M [1 ]
Baron, A [1 ]
机构：
[1] Amylin Pharmaceut Inc, San Diego, CA USA
来源：
DIABETOLOGIA | 2002年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
123
引用
收藏
页码：A43 / A44
页数：2
相关论文
共 50 条
  • [21] Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
    Kendall, DM
    Riddle, MC
    Rosenstock, J
    Zhuang, DL
    Kim, DD
    Fineman, MS
    Baron, AD
    DIABETES CARE, 2005, 28 (05) : 1083 - 1091
  • [22] Exenatide (synthetic exendin-4) continuously improves glucose control over three months in patients with type 2 diabetes
    Taylor, K
    Nielsen, L
    Cole, L
    Han, CJ
    Varns, A
    Kim, D
    Baron, A
    Fineman, M
    Kolterman, O
    DIABETES, 2003, 52 : A130 - A131
  • [23] GLYCEMIC MANAGEMENT USING SIMPLE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN PATIENTS WITH TYPE 2 DIABETES
    Mader, J. K.
    Lilly, L. C.
    Warner, J. L.
    Pieber, T. R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2013, 15 : A138 - A138
  • [24] Risk Factors for Glycemic Control in Hospitalized Patients with Type 2 Diabetes Receiving Continuous Subcutaneous Insulin Infusion Therapy
    Wang, Shun-hua
    Shao, Wei
    Jiang, Qiu-hui
    Zheng, Xuan-ling
    Shen, Qing-bao
    Lin, Xiao-yan
    Zhang, Qiao-qing
    Zhang, Lu-lu
    Shi, Xiu-lin
    Wang, Wen-gui
    Li, Xue-jun
    DIABETES THERAPY, 2023, 14 (01) : 167 - 178
  • [25] Risk Factors for Glycemic Control in Hospitalized Patients with Type 2 Diabetes Receiving Continuous Subcutaneous Insulin Infusion Therapy
    Shun-hua Wang
    Wei Shao
    Qiu-hui Jiang
    Xuan-ling Zheng
    Qing-bao Shen
    Xiao-yan Lin
    Qiao-qing Zhang
    Lu-lu Zhang
    Xiu-lin Shi
    Wen-gui Wang
    Xue-jun Li
    Diabetes Therapy, 2023, 14 : 167 - 178
  • [26] Effect of exenatide (exendin-4) on glycemic control and safety over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
    Buse, J
    Henry, R
    Han, J
    Kim, DD
    Fineman, M
    Baron, AD
    DIABETES, 2004, 53 : A82 - A82
  • [27] Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
    DeFronzo, RA
    Ratner, RE
    Han, J
    Kim, DD
    Fineman, MS
    Baron, AD
    DIABETES CARE, 2005, 28 (05) : 1092 - 1100
  • [28] Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes
    DeFronzo, R
    Ratner, R
    Han, J
    Kim, D
    Fineman, M
    Baron, A
    DIABETOLOGIA, 2004, 47 : A280 - A280
  • [29] Effect of exenatide (exendin-4) on glycemic control and safety over 30 weeks in sulfonylurea-treated patients with Type 2 diabetes
    Buse, J
    Henry, R
    Han, J
    Kim, D
    Fineman, M
    Baron, AD
    DIABETOLOGIA, 2004, 47 : A280 - A280
  • [30] Long-term oral administration of Exendin-4 to control type 2 diabetes in a rat model
    Suzuki, Kenichi
    Kim, Kyoung Sub
    Bae, You Han
    JOURNAL OF CONTROLLED RELEASE, 2019, 294 : 259 - 267
12345